NasdaqGS:RPRXPharmaceuticals
Royalty Pharma Leans Into R&D And AI To Shape Future Royalties
Royalty Pharma (NasdaqGS:RPRX) has entered into a new R&D co-funding agreement with Johnson & Johnson to develop a novel autoimmune therapy.
The company has also appointed a Head of Artificial Intelligence to expand the use of advanced analytics and data science across its operations.
These announcements mark a shift toward greater involvement in drug development and data driven decision making.
Royalty Pharma, known primarily for acquiring biopharma royalties, typically gives investors...